These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9240421)

  • 21. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy.
    Urakami K; Wada K; Arai H; Sasaki H; Kanai M; Shoji M; Ishizu H; Kashihara K; Yamamoto M; Tsuchiya-Ikemoto K; Morimatsu M; Takashima H; Nakagawa M; Kurokawa K; Maruyama H; Kaseda Y; Nakamura S; Hasegawa K; Oono H; Hikasa C; Ikeda K; Yamagata K; Wakutani Y; Takeshima T; Nakashima K
    J Neurol Sci; 2001 Jan; 183(1):95-8. PubMed ID: 11166802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B; Bibl M; Wiltfang J; Steinacker P; Ciesielczyk B; Neubert K; Trenkwalder C; Otto M
    Clin Chem Lab Med; 2006; 44(2):192-5. PubMed ID: 16475906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.
    Buerger K; Zinkowski R; Teipel SJ; Tapiola T; Arai H; Blennow K; Andreasen N; Hofmann-Kiefer K; DeBernardis J; Kerkman D; McCulloch C; Kohnken R; Padberg F; Pirttilä T; Schapiro MB; Rapoport SI; Möller HJ; Davies P; Hampel H
    Arch Neurol; 2002 Aug; 59(8):1267-72. PubMed ID: 12164722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.
    Vanmechelen E; Vanderstichele H; Hulstaert F; Andreasen N; Minthon L; Winblad B; Davidsson P; Blennow K
    Mech Ageing Dev; 2001 Nov; 122(16):2005-11. PubMed ID: 11589918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker].
    Urakami K; Nakashima K
    Rinsho Shinkeigaku; 2002 Nov; 42(11):1162-4. PubMed ID: 12784694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
    PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
    Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
    Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
    de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
    J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias.
    Amadoro G; Corsetti V; Sancesario GM; Lubrano A; Melchiorri G; Bernardini S; Calissano P; Sancesario G
    J Alzheimers Dis; 2014; 42(1):211-26. PubMed ID: 24851856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No added diagnostic value of non-phosphorylated tau fraction (p-tau
    Goossens J; Bjerke M; Struyfs H; Niemantsverdriet E; Somers C; Van den Bossche T; Van Mossevelde S; De Vil B; Sieben A; Martin JJ; Cras P; Goeman J; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
    Alzheimers Res Ther; 2017 Jul; 9(1):49. PubMed ID: 28709448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis.
    Struyfs H; Van Broeck B; Timmers M; Fransen E; Sleegers K; Van Broeckhoven C; De Deyn PP; Streffer JR; Mercken M; Engelborghs S
    J Alzheimers Dis; 2015; 45(3):813-22. PubMed ID: 25633670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.
    Grossman M; Farmer J; Leight S; Work M; Moore P; Van Deerlin V; Pratico D; Clark CM; Coslett HB; Chatterjee A; Gee J; Trojanowski JQ; Lee VM
    Ann Neurol; 2005 May; 57(5):721-9. PubMed ID: 15852395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
    J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progressive supranuclear palsy finally has a clinically measureable τ abnormality.
    Halliday G
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):241. PubMed ID: 25053767
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.